Status:
ACTIVE_NOT_RECRUITING
Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study
Lead Sponsor:
Erasmus Medical Center
Collaborating Sponsors:
Maasstad Hospital
Haaglanden Medical Centre
Conditions:
Hiv
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to determine real-life clinical efficacy of virally suppressed patienst switching to DTG/3TC compared to DTG triple drug cART controls
Detailed Description
Dolutegravir (DTG) based dual antiretroviral therapy constitutes a paradigm shift from triple drug based therapy. Data outside clinical trials are scarce. This study evaluates the value of DTG/3TC in ...
Eligibility Criteria
Inclusion
- Plasma HIVRNA \<50c/mL on triple drug cART regimen including 2NRTI In care in a HIV treatment center in the Netherlands Consented to ATHENA participation
Exclusion
- Documented mutations associated with 3TC or DTG resistance of at least low level Documented inadherence by the treating physician or HepB coinfection (cases only)
Key Trial Info
Start Date :
November 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2026
Estimated Enrollment :
2040 Patients enrolled
Trial Details
Trial ID
NCT04707326
Start Date
November 1 2019
End Date
November 1 2026
Last Update
December 20 2024
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Rijnstate Hospital
Arnhem, Netherlands
2
Catharina Ziekenhuis
Eindhoven, Netherlands
3
Medisch Spectrum Twente
Enschede, Netherlands
4
Admiraal de Ruyter Ziekenhuis
Goes, Netherlands